Biocon to submit more data on Itolizumab to Covid taskforce

The company said that based on the encouraging study results of the pivotal phase 2 conducted by Biocon in India, its US-based partner, Equilllium, is planning to conduct a global randomized controlled clinical trial of Itolizumab in Covid-19 patients for which it will file a US investigational new drug application (IND) soon.

from The Financial Express https://ift.tt/30PxoiA